A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®)

Epigenomics

Volumn 4, Issue 5, 2012, Pages 571-589

  Harrison, Simon J ^a,b   Bishton, Mark ^a   Bates, Susan E ^b   Grant, Steven ^c   Piekarz, Richard L ^d   Johnstone, Ricky W ^a,b   Dai, Yun ^c,d   Lee, Becki ^a   Araujo, Maria E ^a   Prince, H Miles ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

apoptosis; hematology; histone deacetylase inhibitor; malignancy; romidepsin

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; BELINOSTAT; BORTEZOMIB; DEPSIPEPTIDE; ENTINOSTAT; GEMCITABINE; HISTONE ACETYLTRANSFERASE; MOCETINOSTAT; NICOTINAMIDE; PANOBINOSTAT; ROMIDEPSIN; TACEDINALINE; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; AUTOPHAGY; BLOOD TOXICITY; CELL CYCLE REGULATION; CELL PROLIFERATION; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DIARRHEA; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; FATIGUE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; HYPOMAGNESEMIA; IC 50; KIDNEY CARCINOMA; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; SUMOYLATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPREGULATION; VOMITING;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; BORONIC ACIDS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DEPSIPEPTIDES; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOMA, T-CELL, CUTANEOUS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84868523226     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.12.52     Document Type: Article

References (118)

1. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel hist one deacetylase inhibitor. Exp. Cell Res. 241(1), 126-133 (1998). (Pubitemid 28366586)
2. Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-Cell lymphoma. J. Clin. Oncol. 28(29), 4485-4491 (2010).
3. Piekarz RL, Frye R, Turner M et al. Phase II multi-institutional trial of the hist one deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-Cell lymphoma. J. Clin. Oncol. 27(32), 5410-5417 (2009).
4. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002). (Pubitemid 34587077)
5. Kuendgen A, Strupp C, Aivado M et al. Treatment of myelodysplastic syndromes with valproic acid alOne or in combination with all-trans retinoic acid. Blood 104(5), 1266-1269 (2004). (Pubitemid 39166498)
6. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B et al. Phase 1/2 study of the combination of 5-aza-2́- deoxycytidine with valproic acid in patients with leukemia. Blood 108(10), 3271-3279 (2006).
7. Gore SD, Weng LJ, Zhai S et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 7(8), 2330-2339 (2001). (Pubitemid 32751632)
8. Gore SD, Baylin S, Sugar E et al. Combined DNA methyltransferase and hist one deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66(12), 6361-6369 (2006).
9. Bishton M, Kenealy M, JohnstOne R, Rasheed W, HM Prince. Epigenetic targets in hematological malignancies: Combination therapies with HDACis and demethylating agents. Expert Rev. Anticancer Ther. 7(10), 1439-1449 (2007). (Pubitemid 351826909)
10. Prince HM, Bishton MJ, Harrison SJ. Clinical studies of hist one deacetylase inhibitors. Clin. Cancer Res 15(12), 3958-3969 (2009).
11. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Hist one deacetylases: Unique players in shaping the epigenetic hist one code. Ann. NY Acad. Sci. 983, 84-100 (2003). (Pubitemid 36399322)
12. Kim JY, Casaccia P. HDAC1 in axonal degeneration: A matter of subcellular localization. Cell Cycle 9(18), 3680-3684 (2010).
13. Kim JY, Shen S, Dietz K et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat. Neurosci. 13(2), 180-189 (2010).
14. Sakai H, Urano T, Ookata K et al. MBD3 and HDAC1, two compOnents of the NuRD complex, are localized at aurora-A-Positive centrosomes in M phase. J. Biol. Chem. 277(50), 48714-48723 (2002). (Pubitemid 35470836)
15. Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-Ribosyltransferase activity. Biochem. Biophys. Res. Commun. 260(1), 273-279 (1999). (Pubitemid 29351819)
16. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 23(17), 3971-3993 (2005). (Pubitemid 46218700)
17. Bolden JE, Peart MJ, JohnstOne RW. Anticancer activities of hist one deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006). (Pubitemid 44348499)
18. Dokmanovic M, Marks PA. Prospects: Hist one deacetylase inhibitors. J. Cell. Biochem. 96(2), 293-304 (2005). (Pubitemid 41437862)
19. Ueda H, Nakajima H, Hori Y et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. I. Taxonomy, fermentation, isolation, physico-Chemical and biological properties, and antitumor activity. J. Antibiot. (Tokyo) 47(3), 301-310 (1994). (Pubitemid 24106520)
20. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-Ras transformed NIH3T3 cells. Biosci. Biotechnol. Biochem. 58(9), 1579-1583 (1994). (Pubitemid 2159869)
21. Lee JS, Paull K, Alvarez M et al. Rhodamine efflux patterns predict P-Glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46(4), 627-638 (1994). (Pubitemid 24334752)
22. Sandor V, Bakke S, Robey RW et al. Phase I trial of the hist one deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8(3), 718-728 (2002). (Pubitemid 34742100)
23. Isodax®, package insert. Celgene Corporation, NJ, USA
24. Berg SL, StOne J, Xiao JJ et al. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother. Pharmacol. 54(1), 85-88 (2004). (Pubitemid 38858370)
25. Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I hist one deacetylases. Cancer Res. 62(17), 4916-4921 (2002). (Pubitemid 34984414)
26. Bradner JE, West N, Grachan ML et al. Chemical phylogenetics of hist one deacetylases. Nat. Chem. Biol. 6(3), 238-243 (2010).
27. Ruefli AA, Ausserlechner MJ, Bernhard D et al. The hist one deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl Acad. Sci. USA 98(19), 10833-10838 (2001). (Pubitemid 32878706)
28. Rosato RR, Almenara JA, Maggio SC et al. Role of hist one deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol. Cancer Ther. 7(10), 3285-3297 (2008).
29. Subramanian C, Opipari AW Jr, Bian X, Castle VP, Kwok RP. Ku70 acetylation mediates neuroblastoma cell death induced by hist one deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102(13), 4842-4847 (2005). (Pubitemid 40471541)
30. Rosato RR, Kolla SS, Hock SK et al. Hist one deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-Related pathway. J. Biol. Chem. 285(13), 10064-10077 (2010).
31. Yi C, Ma M, Ran L et al. Function and molecular mechanism of acetylation in autophagy regulation. Science 336(6080), 474-477 (2012).
32. Robert T, Vanoli F, Chiolo I et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471(7336), 74-79 (2011).
33. Vrana JA, Decker RH, Johnson CR et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-xL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18(50), 7016-7025 (1999). (Pubitemid 30028872)
34. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Hist one deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated hist one acetylation. Proc. Natl Acad. Sci. USA 97(18), 10014-10019 (2000).
35. Waby JS, Chirakkal H, Yu C et al. Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol. Cancer 9, 275 (2010).
36. Brazelle W, Kreahling JM, Gemmer J et al. Hist one deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. Plos One 5(12), e14335 (2010).
37. Noh EJ, Lim DS, Jeong G, Lee JS. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem. Biophys. Res. Commun. 378(3), 326-331 (2009).
38. Stevens FE, Beamish H, Warrener R, Gabrielli B. Hist one deacetylase inhibitors induce mitotic slippage. Oncogene 27(10), 1345-1354 (2008). (Pubitemid 351317466)
39. Warrener R, Beamish H, Burgess A et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 17(11), 1550-1552 (2003).
40. Robbins AR, Jablonski SA, Yen TJ et al. Inhibitors of hist one deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 4(5), 717-726 (2005). (Pubitemid 41353858)
41. Harrison SJ, Quach H, Link E et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasOne in relapsed or refractory multiple myeloma. Blood 118(24), 6274-6283 (2011).
42. Mitsiades N, Mitsiades CS, Richardson PG et al. Molecular sequelae of hist one deacetylase inhibition in human malignant B cells. Blood 101(10), 4055-4062 (2003). (Pubitemid 36857886)
43. Duan H, Heckman CA, Boxer LM. Hist one deacetylase inhibitors down-Regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol. Cell. Biol. 25(5), 1608-1619 (2005). (Pubitemid 40280131)
44. Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH. Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin. Cancer Res. 6(2), 681-692 (2000). (Pubitemid 30111494)
45. Dhordain P, Lin RJ, Quief S et al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/hist one deacetylase containing complex to mediate transcriptional repression.Nucleic Acids Res 26(20), 4645-4651 (1998). (Pubitemid 28466611)
46. Pasqualucci L, Bereschenko O, Niu H et al. Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6. Leuk. Lymphoma 44(SUPPL3), S5-S12 (2003). (Pubitemid 38196057)
47. Kawamata N, Koeffler HP. Mantle cell lymphoma: SAHA blocks Akt/mTOR pathway and reduces cyclin D1 protein levels by affecting translation. ASH Annual Meeting Abstracts 104(11), 3293 (2004).
48. Catley L, Weisberg E, Tai Y-T et al. NVP-LAQ824 is a potent novel hist one deacetylase inhibitor with significant activity against multiple myeloma. Blood 102(7), 2615-2622 (2003). (Pubitemid 37193603)
49. Peart MJ, Smyth GK, Van Laar RK et al. Identification and functional significance of genes regulated by structurally different hist one deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102(10), 3697-3702 (2005). (Pubitemid 40354674)
50. Mitsiades CS, Mitsiades NS, McMullan CJ et al. Transcriptional sig nature of hist one deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc. Natl Acad. Sci. USA 101(2), 540-545 (2004). (Pubitemid 38084672)
51. Nebbioso A, Clarke N, Voltz E et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11(1), 77-84 (2005). (Pubitemid 40215841)
52. Maeda T, Towatari M, Kosugi H, Saito H. Up-Regulation of costimulatory/adhesion molecules by hist one deacetylase inhibitors in acute myeloid leukemia cells. Blood 96(12), 3847-3856 (2000).
53. Magner WJ, Kazim AL, Stewart C et al. Activation of MHC class I, II, and CD40 gene expression by hist one deacetylase inhibitors. J. Immunol. 165(12), 7017-7024 (2000). (Pubitemid 32001174)
54. Inoue S, Macfarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. Hist one deacetylase inhibitors potentiate TNF-Related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 11(SUPPL2), S193-S206 (2004).
55. Aron JL, Parthun MR, Marcucci G et al. Depsipeptide (FR901228) induces hist one acetylation and inhibition of hist one deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-Regulation of c-FLIP protein. Blood 102(2), 652-658 (2003). (Pubitemid 36841988)
56. Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin. Cancer Res. 14(2), 549-558 (2008). (Pubitemid 351226125)
57. Khan SB, Maududi T, Barton K, Ayers J, Alkan S. Analysis of hist one deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br. J. Haematol. 125(2), 156-161 (2004). (Pubitemid 38534966)
58. Piekarz RL, Robey RW, Zhan Z et al. T-Cell lymphoma as a model for the use of hist one deacetylase inhibitors in cancer therapy: Impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103(12), 4636-4643 (2004). (Pubitemid 38745996)
59. Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin. Cancer Res. 12(5), 1547-1555 (2006).
60. Peart MJ, Tainton KM, Ruefli AA et al. Novel mechanisms of apoptosis induced by hist one deacetylase inhibitors. Cancer Res. 63(15), 4460-4471 (2003). (Pubitemid 36951018)
61. Choudhary C, Kumar C, Gnad F et al. Lysine acetylation targets protein complexes and co-Regulates major cellular functions. Science 325(5942), 834-840 (2009).
62. Terui T, Murakami K, Takimoto R et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by hist one deacetylase inhibitors. Cancer Res. 63(24), 8948-8954 (2003). (Pubitemid 38064075)
63. Subramanian C, Jarzembowski JA, Opipari AW Jr, Castle VP, Kwok RP. HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma. Neoplasia 13(8), 726-734 (2011).
64. Bishton MJ, Harrison SJ, Martin BP et al. Deciphering the molecular and biological processes that mediate hist one deacetylase inhibitor-induced thrombocytopenia. Blood 117(13), 3658-3668 (2011).
65. Yu X, Guo ZS, Marcu MG et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94(7), 504-513 (2002). (Pubitemid 34411289)
66. To KK, Robey R, Zhan Z, Bangiolo L, Bates SE. Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway. Mol. Cancer Res. 9(4), 516-527 (2011).
67. Wang Y, Wang SY, Zhang XH et al. FK228 inhibits Hsp90 chaperOne function in K562 cells via hyperacetylation of Hsp70. Biochem. Biophys. Res. Commun. 356(4), 998-1003 (2007). (Pubitemid 46529390)
68. Sasakawa Y, Naoe Y, Noto T et al. Antitumor efficacy of FK228, a novel hist one deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol. 66(6), 897-906 (2003). (Pubitemid 37083586)
69. Mie Lee Y, Kim SH, Kim HS et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific hist one deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun. 300(1), 241-246 (2003).
70. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Hist one deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol. Cell. Biol. 26(6), 2019-2028 (2006). (Pubitemid 43346906)
71. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 132(1), 27-42 (2008).
72. Oh M, Choi IK, Kwon HJ. Inhibition of hist one deacetylase1 induces autophagy. Biochem. Biophys. Res. Commun. 369(4), 1179-1183 (2008).
73. Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, Sakamoto KM. Role of the aggresome pathway in cancer: Targeting hist one deacetylase 6-dependent protein degradation. Cancer Res. 68(8), 2557-2560 (2008). (Pubitemid 351556250)
74. Watanabe M, Adachi S, Matsubara H et al. Induction of autophagy in malignant rhabdoid tumor cells by the hist one deacetylase inhibitor FK228 through AIF translocation. Int. J. Cancer 124(1), 55-67 (2009).
75. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and hist one deacetylase inhibitors. Clin. Cancer Res. 10(11), 3839-3852 (2004). (Pubitemid 38697620)
76. Bali P, Pranpat M, Bradner J et al. Inhibition of hist one deacetylase 6 acetylates and disrupts the chaperOne function of heat shock protein 90: A novel basis for antileukemia activity of hist one deacetylase inhibitors. J. Biol. Chem. 280(29), 26729-26734 (2005). (Pubitemid 41040705)
77. Nawrocki ST, Carew JS, Pino MS et al. Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66(7), 3773-3781 (2006).
78. Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE, JohnstOne RW. Characterisation of the novel apoptotic and therapeutic activities of the hist one deacetylase inhibitor romidepsin. Mol. Cancer Ther. 7(5), 1066-1079 (2008).
79. Fiebig AA, Zhu W, Hollerbach C, Leber B, Andrews DW. Bcl-xL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 6, 213 (2006).
80. Sasakawa Y, Naoe Y, Inoue T et al. Effects of FK228, a novel hist one deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol. 64(7), 1079-1090 (2002). (Pubitemid 35247815)
81. Roychowdhury S, Baiocchi RA, Vourganti S et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-Positive lymphoproliferative disorder. J. Natl Cancer. Inst. 96(19), 1447-1457 (2004). (Pubitemid 39429669)
82. Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin. Cancer Res. 16(2), 554-565.
83. Byrd JC, Shinn C, Ravi R et al. Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-Cell chronic lymphocytic leukemia cells. Blood 94(4), 1401-1408 (1999). (Pubitemid 29380421)
84. Klisovic DD, Katz SE, Effron D et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest. Ophthalmol. Vis. Sci. 44(6), 2390-2398 (2003). (Pubitemid 36618393)
85. Sawa H, Murakami H, Kumagai M et al. Hist one deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo. Acta Neuropathol. (Berl.) 107(6), 523-531 (2004). (Pubitemid 38765394)
86. Marshall JL, Rizvi N, Kauh J et al. A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2(6), 325-332 (2002). (Pubitemid 35265981)
87. Byrd JC, Marcucci G, Parthun MR et al. A Phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105(3), 959-967 (2005). (Pubitemid 40170861)
88. Piekarz RL, Frye R, Turner M et al. Completion of the first cohort of patients with cutaneous T-Cell lymphoma enrolled on a Phase II trial of depsipeptide. ASH Annual Meeting Abstracts 106(11), 231 (2005).
89. Niesvizky R, Ely S, Diliberto M et al. Multicenter Phase II trial of the hist one deacetylase inhibitor depsipeptide (FK228) for the treatment of relapsed or refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 106(11), 2574 (2005).
90. Whitehead RP, Mccoy S, Wollner IS et al. Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either One or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study. J. Clin. Oncol. (Meeting Abstracts) 24(SUPPL18), 3598 (2006).
91. Su YB, Tuttle RM, Fury M et al. A Phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-Refractory, metastatic, thyroid carcinoma: Preliminary toxicity and efficacy experience. J. Clin. Oncol. (Meeting Abstracts) 24(SUPPL18), 5554 (2006).
92. Molife R, Patterson S, Riggs C et al. Phase II study of FK228 in patients with hormOne refractory prostate cancer (HRPC). J. Clin. Oncol. (Meeting Abstracts) 24(SUPPL18), 14554 (2006).
93. Whittaker S, McCulloch W, Robak T, Baran E, Prentice A; All Investigators. International multicenter Phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-Cell lymphoma (CTCL): Interim report. J. Clin. Oncol. (Meeting Abstracts) 24(SUPPL18), 3063 (2006).
94. Piekarz RL, Frye AR, Wright JJ et al. Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-Cell lymphoma. Clin. Cancer Res. 12(12), 3762-3773 (2006). (Pubitemid 44000258)
95. Cabell C, Bates S, Piekarz R et al. Systematic assessment of potential cardiac effects of the novel hist one deacetylase (HDAC) inhibitor romidepsin. ASH Annual Meeting Abstracts 114(22), 3709 (2009).
96. Morgan M, MalOney D, Duvic M. Hypomagnesemia and hypocalcemia in mycosis fungoides: A retrospective case series. Leuk. Lymphoma 43(6), 1297-1302 (2002). (Pubitemid 34537976)
97. Piekarz RL, Robey R, Sandor V et al. Inhibitor of hist one deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-Cell lymphoma: A case report. Blood 98(9), 2865-2868 (2001).
98. Bates SE, Zhan Z, Steadman K et al. Laboratory correlates for a Phase II trial of romidepsin in cutaneous and peripheral T-Cell lymphoma. Br. J. Haematol. 148(2), 256-267 (2010).
99. Nebozhyn M, Loboda A, Kari L et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 107(8), 3189-3196 (2006).
100. Piekarz R, Frye R, Wright J et al. Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-Cell lymphoma. J. Clin. Oncol. (Meeting Abstracts) 25(SUPPL18), 8027- (2007).
101. Piekarz RL, Frye R, Prince HM et al. Phase 2 trial of romidepsin in patients with peripheral T-Cell lymphoma. Blood 117(22), 5827-5834 (2011).
102. Coiffier B, Pro B, Prince HM et al. Results from a pivotal, open-label, Phase II study of romidepsin in relapsed or refractory peripheral T-Cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30(6), 631-636 (2012).
103. Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin. Cancer Res. 16(2), 554-565 (2010).
104. Dupuis J, Casasnovas RO, Morschhauser F et al. Early results of a Phase Ib/II dose-escalation trial of romidepsin in association with CHOP in patients with peripheral T-Cell lymphomas (PTCL). ASH Annual Meeting Abstracts 118(21), 2673 (2011).
105. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 24(10), 1760-1768 (2010).
106. Niesvizky R, Ely S, Mark T et al. Phase 2 trial of the hist one deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 117(2), 336-342 (2011).
107. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with hist one deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102(10), 3765-3774 (2003). (Pubitemid 37409399)
108. Catley L, Weisberg E, Kiziltepe T et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 108(10), 3441-3449 (2006).
109. Sutheesophon K, Kobayashi Y, Takatoku MA et al. Hist one deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol. 115(1-2), 78-90 (2006). (Pubitemid 43130438)
110. Berenson JR, Yellin O, Mapes R et al. A Phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease. J. Clin. Oncol. (Meeting Abstracts) 27(15S), e19508 (2009).
111. Klimek VM, Fircanis S, Maslak P et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 14(3), 826-832 (2008). (Pubitemid 351231166)
112. Odenike OM, Alkan S, Sher D et al. Hist one deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin. Cancer Res. 14(21), 7095-7101 (2008).
113. Schrump DS, Fischette MR, Nguyen DM et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin. Cancer Res. 14(1), 188-198 (2008). (Pubitemid 351377995)
114. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A Phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 5(1), 57-60 (2006).
115. Whitehead RP, Rankin C, Hoff PM et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A Southwest Oncology Group study (S0336). Invest. New Drugs 27(5), 469-475 (2009).
116. Molife LR, Attard G, Fong PC et al. Phase II, two-stage, single-arm trial of the hist one deacetylase inhibitor (HDACi) romidepsin in metastatic castration-Resistant prostate cancer (CRPC). Ann. Oncol. 21(1), 109-113 (2010).
117. Doss HH, Jones SF, Infante JR et al. A Phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. J. Clin. Oncol. 26(Suppl.), Abstract 2567 (2008) .
118. Luchenko VL, Salcido CD, Zhang Y et al. Schedule-dependent synergy of hist one deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle 10(18), 3119-3128 (2011).